.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Shella Saint Fleur-Lominy, MD, PhD

Articles

Dr. Fleur-Lominy on Targeted Pathways in MPNs

June 15th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.

Dr. Fleur-Lominy on the Current Sequencing Strategy in MPNs

April 28th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Dr. Saint Fleur-Lominy on Remaining Challenges in Myelofibrosis

April 8th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Dr. Saint Fleur-Lominy on the Use of Ruxolitinib Versus Fedratinib in MPNs

March 25th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Dr. Saint Fleur-Lominy on the Role of Transplant in MPNs

March 20th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Dr. Saint Fleur-Lominy on Emerging Agents in MPNs

March 19th 2020

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Dr. Saint Fleur-Lominy on Differences Between Ruxolitinib and Fedratinib in MPNs

March 16th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Saint Fleur-Lominy on Impact of Ruxolitinib on Symptom Burden in MPNs

March 5th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.